

PKD2 influence uric acid levels and gout risk

by interacting with *ABCG2*

Zheng Dong¹, Jingru Zhou¹, Shuai Jiang¹, Yuan Li¹, Dongbao Zhao², Chengde Yang³, Yanyun Ma¹, Hongjun He⁴, Hengdong Ji⁵, Li Jin^{1,6}, Hejian Zou^{7,8}, Jiucun Wang^{1, 6,8}

¹ State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University Jiangwan Campus, Shanghai, China.

² Division of Rheumatology and Immunology, Changhai Hospital, Shanghai, China.

³ Division of Rheumatology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

⁴ Division of Rheumatology, Taixing People's Hospital, Jiangsu Province, China.

⁵ Division of Rheumatology, Taizhou People's Hospital, Jiangsu Province, China.

⁶ Fudan-Taizhou Institute of Health Sciences, Taizhou, Jiangsu Province, China.

⁷ Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China.

⁸ Institute of Rheumatology, Immunology and Allergy, Fudan University, Shanghai, China.

Address corresponding to Jiucun Wang, Ph.D, School of Life Sciences, Fudan University, 2005 Songhu Road, Shanghai 200438, People's Republic of China. (e-mail: jcwang@fudan.edu.cn).

Abstract

Background: Uric acid is the final product of purine metabolism and elevated serum urate levels can cause gout. Conflicting results were reported for the effect of *PKD2* on serum urate levels and gout risk. Therefore, our study attempted to state the important role of *PKD2* in influencing the pathogenesis of gout.

Method: SNPs in *PKD2* (rs2725215 and rs2728121) and *ABCG2* (rs2231137 and rs1481012) were tested in approximately 5,000 Chinese individuals.

Results: Two epistatic interactions between loci in *PKD2* (rs2728121) and *ABCG2* (rs1481012 and rs2231137) showed distinct contributions to uric acid levels with P_{int} values of 0.018 and 0.004, respectively, and the associations varies by gender and BMI. The SNP pair of rs2728121 and rs1481012 justly played roles in uric acid in females ($P_{\text{int}} = 0.006$), while the other pair did in males ($P_{\text{int}} = 0.017$). Regarding BMI, the former SNP pair merely contributed in overweigh subjects ($P_{\text{int}} = 0.022$) and the latter one did in both normal and overweigh individuals ($P_{\text{int}} = 0.013$ and 0.047, respectively). Furthermore, the latter SNP pair was also associated with gout pathology ($P_{\text{int}} = 0.001$), especially in males ($P_{\text{int}} = 0.001$). Finally, functional analysis showed potential epistatic interactions in those genes region and *PKD2* mRNA expression had a positive correlation with *ABCG2*'s ($r = 0.743$, $P = 5.83\text{e-}06$).

Conclusion: Our study for the first time identified that epistatic interactions between *PKD2* and *ABCG2* influenced serum urate concentrations and gout risk, and *PKD2* might affect the pathogenesis from elevated serum urate to hyperuricemia to gout by modifying *ABCG2*.

Key words: epistatic, serum urate, body mass index (BMI), Smoking, gender, enhancer

Introduction

Uric acid is the end breakdown product of purine complex in human beings and high uric acid levels in the blood (hyperuricemia) leads to the deposition of monosodium urate (MSU) crystals in the joints and tissues, which plays a predominant role in the development of gout (Dehghan et al. 2008; Yang et al. 2010; Köttgen et al. 2012; Perez-Ruiz et al. 2014; Dong et al. 2017b). Gout is one acute

inflammatory arthritis (Dong and Wang 2015; Dong et al. 2017a) and affects a large number of individuals in many countries (Zhu et al. 2011; Dong et al. 2015a). Hyperuricemia is able to cause gout (Dong et al. 2015b), but not all hyperuricemia patients develop gout (Merriman 2015). Generally, only a quarter of hyperemia patients finally develop gout, indicating that hyperuricemia is necessary but not sufficient for gout (Merriman 2015). Nowadays, several loci in different genes have been identified to affect serum urate concentration and gout risk (Köttgen et al. 2012; Merriman 2015). However, those loci only explained a fraction of heredity of serum urate/gout and some of them contribute differently to the pathogenesis from elevated serum urate to hyperuricemia to gout (Köttgen et al. 2012; Dong et al. 2017b). And epistasis had been proved to affect complex traits and played important roles in various biological functions (Cordell 2002; Phillips 2008). Therefore, it is urgent to test the effect of epistatic interactions of genes on the development from elevated serum urate to hyperuricemia to gout.

In addition, recent studies found *PKD2* associated with uric acid and gout (Zhang et al. 2016), while other researchers had an opposite opinion (Dehghan et al. 2008). The conflicting results for the effect of *PKD2* on serum urate levels and gout risk is a challenge topic which need more evidences to obtain a reliable conclusion. In addition, a suggestive epistatic interaction for regulating serum urate concentrations had been reported in the gene region of *PKD2* and *ABCG2*

(Wei et al. 2014). Therefore, epistasis analysis of *PKD2* and *ABCG2* might obtain a new evidence for this conflict and provide an explanation to extra heredity of serum urate and gout.

In the present study, we aim to study epistasis between *PKD2* and *ABCG2* applying a four-step approach. Firstly, the effect of loci interactions on serum urate was studied. Then the candidate urate-related interactions were tested in hyperuricemia and gout patients. Other heterogeneity factors, including gender, body mass index (BMI) and smoking status, influence on above significant associations were also considered in our analysis. In addition, further functional analysis was performed to provide more proof about the interactions. Finally, the relation of mRNA expression between *PKD2* and *ABCG2* were investigated. Through this strategy, the present study for the first time found that epistatic interactions between *PKD2* and *ABCG2* contributed to serum urate concentrations and gout risk, and *PKD2* might influence the pathogenesis from elevated serum urate to hyperuricemia to gout by modifying *ABCG2*.

Methods and materials

Study subjects

The present study was approved by the Ethical Committees of the School of Life Sciences of Fudan University (approval number of 140) and was conducted in accordance with the principles of the Declaration of Helsinki. All subjects in this study provided their written informed. All of 582 gout patients were diagnosed with gout (OMIM: #138900) following the American College of Rheumatology diagnostic criteria (Wallace et al. 1977), came from Changhai Hospital, Taixing People's Hospital and Taizhou People's Hospital. And gout patients did not use any urate-lowering drugs two weeks before sample collection.

Furthermore, 4332 individuals with no history of gout were selected from the Taizhou Longitudinal Study (Wang et al. 2009). Those subjects were divided into subgroups based on their

smoking status recorded in questionnaires, and body mass index (BMI) values according to the categories of the World Health Organization (WHO) (Yang et al. 2016; Dong et al. 2017b). Smoking status contained non-smoker, former smoker and current smoker. Regarding BMI, three subgroups (underweight: BMI < 18.5; normal weight: $18.50 \leq \text{BMI} < 25$; overweight: BMI ≥ 25) were divided in this study. Among them, 1387 subjects were treated as hyperuricemia patients due to their high serum urate levels ($> 417 \text{ umol/L}$) (Khanna et al. 2012), and the others were treated as healthy controls. The detail characteristics of the participants in this study are illustrated in Supplementary Material, Table S1.

SNP genotype and Real-time qPCR

Peripheral blood was collected from all participants in this study and DNA was extracted from blood samples. RNA was isolated from blood cells of 58 male healthy subjects. Detail information of experimental approaches for DNA and RNA had been described in our previous study (Dong et al. 2017b). Genotyping of SNPs in *PKD2* (rs2725215 and rs2728121) and *ABCG2* (rs2231137 and rs1481012) was processed by SNaPshot. And the gene relative expression was tested using real-time qPCR.

Bioinformatics analysis

Two *PKD2* SNPs sets were used in this study. One (set one) was SNPs associated with serum urate reaching genome-wide significance levels in a recent genome-wide association study (Köttgen et al. 2012). Another (set two) was all SNPs in the gene region of *PKD2*. Cell-type-specific enhancer enrichment analysis was performed in both two sets using HaploReg (<http://archive.broadinstitute.org/mammals/haploreg/haploreg.php>) (Ward and Kellis 2012). SNPnexus (Dayem Ullah et al. 2013) and UCSC genome browser (Kent et al. 2002) were applied

for the functional annotation of loci. Enlight (<http://enlight.wglab.org>) was used to draw regional plot and show epigenetic modification (Guo et al. 2015). In addition, linkage disequilibrium (LD) relationships among target SNPs were tested and generated LD plots using SNAP (<http://archive.broadinstitute.org/mpg/snap/index.php>) (Johnson et al. 2008).

Statistical analysis

P-value of SNP pair affected on serum urate concentrations was calculated by linear regression adjusted age, gender and target SNPs. Variance explained of SNP pair in serum urate was calculated by linear regression. And *P*-value of SNP pair in hyperuricemia and gout were calculated by logistic regression adjusted age, gender and target SNPs. Furthermore, subgroups analysis of gender, BMI and smoking status were also performed. In addition, the mRNA expression correlation between *PKD2* and *ABCG2* was analyzed in our study. *P* values less than 0.05 were considered statistically significant and all statistical analyses were processed by using R (Version 3.0.2: www.r-project.org/).

Results

Epistatic interactions of *PDK2* and *ABCG2* contributed to serum urate concentrations

A total of four SNP pairs were tested in our study. Of them, two SNP pairs (rs2728121:rs1481012 and rs2728121:rs2231137) were identified to associate with the concentrations of serum urate (Estimate = -14.487, $P_{\text{int}} = 0.018$ and Estimate = 9.781, $P_{\text{int}} = 0.004$, respectively), while other pairs did not ($P_{\text{int}} = 0.181$ and $P_{\text{int}} = 0.270$, respectively) (Table 1). The former SNP pair (rs2728121:rs1481012) could explain 0.099% of uric acid variance without conditioning on the marginal SNPs, and the later pair (rs2728121:rs2231137) could explain 0.164% of the variance (Table 1).

In addition, the present study showed that the significant association between SNP pairs and serum urate were modified by gender (Table 1). In males, the latter interaction pair exhibited an effect on uric acid (Estimate = 8.980, $P_{\text{int}} = 0.017$) while the former interaction pair did not ($P_{\text{int}} = 0.379$). In contrast to female subjects, the former interaction pair contributed to the concentrations of serum urate (Estimate = -33.315, $P_{\text{int}} = 0.006$) while the latter interaction pair did not ($P_{\text{int}} = 0.171$). Interestingly, the explanation of former interaction pair on uric acid variance achieved 0.493% in female, suggesting an important influence of epistasis between *PKD2* and *ABCG2* on serum urate.

Epistatic interactions of *PDK2* and *ABCG2* affected gout risk

Because elevated serum urate is a critical risk factor for the development of hyperuricemia and gout. We further checked the contributions of epistatic interactions of *PDK2* and *ABCG2* on hyperuricemia and gout. Regards hyperuricemia, the former interaction pair justly affected the hyperuricemia risk in females (Estimate = -0.648, $P_{\text{int}} = 0.017$) (Table 2), but did not in males ($P_{\text{int}} = 0.483$). In opposite of the former pair, the latter pair associated with hyperuricemia in males with P_{int} value of 0.018, but did not in females ($P_{\text{int}} = 0.427$). With combination of males and females, the latter pair also influenced the pathogenesis of hyperuricemia (Estimate = 0.193, $P_{\text{int}} = 0.009$). For the development from hyperuricemia to gout, the latter pair played an significant role in this translation (Estimate = 0.313, $P_{\text{int}} = 0.035$), especially in males (Estimate = 0.338, $P_{\text{int}} = 0.030$) (Table 2). However, the former pair showed not significant association with this translation in both subgroup of male and female ($P_{\text{int}} = 0.444$ and $P_{\text{int}} = 0.577$, respectively). Due to the contribution of the latter pair in the pathogenesis from elevated serum urate to hyperuricemia to gout, it distinctly affected the risk of gout (Estimate = 0.480, $P_{\text{int}} = 0.001$), especially for male individuals (Estimate = 0.524, $P_{\text{int}} = 0.001$).

Association between epistatic interactions and serum urate in BMI and smoking subgroups

Our previous studies have suggested that body mass index (BMI) and cigarette smoking could affect uric acid levels (Dong et al. 2015b, 2017b; Yang et al. 2016), while their contributions on the association between epistasis and serum urate was elusive. Therefore, we performed further analysis in the BMI and smoking status subgroups.

After analyzed in BMI subgroups, the latter pair was identified to be associated with uric acid in normal subjects (Estimate = 11.456, $P_{\text{int}} = 0.013$) and overweight individuals (Estimate = 9.844, $P_{\text{int}} = 0.047$) (Table 3). And the former pair only affected the concentrations of serum urate in overweight subgroup (Estimate = -21.702, $P_{\text{int}} = 0.022$). However, no significant associations were found in the subgroup of underweight with all P -values larger than 0.05. Regards smoking status, both SNP pairs did not influence uric acid levels (Table 3).

Functional analysis for identified SNP pairs

Chromatin states analysis was performed in the gene region of *PKD2* and *ABCG2*, showing several strong and weak enhancers located at this region, especially at the gene region of *PKD2* (Supplementary material Figure 1 and 2). Consistent with this result, many other functional factors, such as transcription factor and DNase factor, were also identified in *PKD2* gene region (Supplementary material Figure 1 and 2). Our results suggested a potential regulate effect in those genes region, especially in *PKD2*. In addition, *ABCG2* had been identified with function as urate transporter in previous studies (Woodward et al. 2009; Köttgen et al. 2012; Dong et al. 2015a). Above all, we hypothesized that *PKD2* influenced serum urate by epistatic interacting with *ABCG2*.

To further analyze the regulation function in *PKD2* region, two SNP sets in this region were tested using enhancer enrichment analysis (Table 4). For set one, we found significant enrichments of enhancers in Huvec cell line (3.6-fold enrichment, $P = 0.012$), especially for strong enhancers (5.7-

fold enrichment, $P = 0.005$) (Table 4). More significant enhancer enrichments were found for set two and those enrichments were existed in various cell lines (H1, HepG2, Huvec, HSMM, NHLF, HMEC, GM12878 and NHEK cell lines) (Table 4). All those results revealed that regulation factors in *PKD2* might played an important role in controlling the concentrations of serum urate by epistatic interacting with *ABCG2*.

The mRNA expression correlation between *PKD2* and *ABCG2*

To further validate the potential epistatic influence in *PKD2* region, the mRNA expression correlation between *PKD2* and *ABCG2* was studied. Our result showed that *PKD2* mRNA expression was positive correlation with *ABCG2* mRNA expression ($r = 0.743$, $P = 5.83e-06$) (Figure 1), suggested the potential effect of regulation factor in *PKD2* on modification of *ABCG2* expression.

Discussion

This study explored the epistatic interaction between *PKD2* and *ABCG2* affecting the pathogenesis from elevated serum urate to hyperuricemia to gout and found two SNP pairs (rs2728121:rs1481012 and rs2728121:rs2231137) significantly associated with serum urate and/or gout. The SNP pairs identified in the association study were analyzed in detail, including the analysis of association among subgroups of heterogeneity factors (such as gender, body mass index (BMI) and smoking status), functional analysis and mRNA expression analysis.

ABCG2 gene encoded a urate transporter and contributed to serum urate concentration and gout risk. It had been proved to be one of strongest risk factor for the development of gout (Köttgen et al. 2012; Dong et al. 2015a). But the results for the association between *PKD2* and uric acid/gout is contradictory. Recent studies suggested that *PKD2* associated with uric acid and gout (Zhang et

al. 2016), while other researchers had an opposite opinion (Dehghan et al. 2008). In addition, no functional experiment showed that *PKD2* directly affect the concentration of serum urate and gout risk. Therefore, this study attempted to provide more evidences to obtain a reliable conclusion.

Previous study had been suggested the important role of epistatic interaction in the 4p16.1 region regulating uric acid levels and showed a suggestive interaction pair in the gene region of *PKD2* (Wei et al. 2014). Therefore, this study focused on the epistasis effect in *PKD2* and *ABCG2* gene region. The present study showed that two epistatic interaction pairs (rs2728121:rs1481012 and rs2728121:rs2231137) were identified to associate with the concentrations of serum urate (Estimate = -14.487, P_{int} = 0.018 and Estimate = 9.781, P_{int} = 0.004, respectively) and the latter pair (rs2728121: rs2231137) was also associated with gout (P_{int} = 0.001) (Table 1 and 2). The results provided a new view for explaining the influence of *PKD2* on serum urate/gout. *PKD2* could contribute to the pathogenesis from elevated serum urate to hyperuricemia to gout by an indirect way as interacting with *ABCG2*. Although the direct function of *PKD2* in influencing the pathogenesis could not identified in this study, it provided a new evidence to state that *PKD2* is a urate/gout-associated gene. Our study also found that the former interaction pair could explain 0.099% of uric acid variance especially 0.493% in female, and the later interaction pair could explain 0.164% of the variance (Table 1), suggesting epistasis effect is helpful to solve the ‘missing heritability’ problem. In addition, in consistent with our previous results (Dong et al. 2015b, 2017b; Yang et al. 2016). Environment factors, such as gender and BMI modified the associations between SNP pairs and serum urate/gout in the present study (Table 3).

The mechanism of the interactions between genes were analyzed by functional analysis and mRNA expression analysis. The functional analysis showed that regulation factors enrichment into the gene region of *PKD2*, indicating the potential regulation function of *PKD2* to *ABCG2*. To further

analyze this result, mRNA expression correlation between genes was used. The result suggested a positive correlation between *PKD2* mRNA expression and *ABCG2* mRNA expression, further supporting our hypothesis that *PKD2* influenced serum urate by epistatic interacting with *ABCG2*.

In conclusion, this study for the first time suggested that epistatic interactions between *PKD2* and *ABCG2* influenced serum urate concentrations and gout risk, and *PKD2* might affect the pathogenesis from elevated serum urate to hyperuricemia to gout by modifying *ABCG2*. Furthermore, our study provided a new evidence to support that *PKD2* is a urate/gout-associated gene and indicated that epistasis effect is helpful to solve the ‘missing heritability’ problem.

Acknowledgements

General: Computational support was provided by the High-End Computing Center located at Fudan University.

Funding: This work was supported by grants from the Science and Technology Committee of Shanghai Municipality [11DJ1400100 to J.W.], International S&T Cooperation Program of China [2013DFA30870 to J.W.], Ministry of Science and Technology [2011BAI09B00 to J.W.], and Program for 2012 Outstanding Medical Academic Leader for Hejian Zou.

Author contributions: Conceived and designed the experiments: JW ZD. Performed the experiments: ZD. Analyzed the data: ZD. Contributed reagents/materials/analysis tools: JZ DZ CY YM HH HJ SJ YL. Wrote the paper: JW ZD HZ LJ.

COMPLIANCE WITH ETHICS GUIDELINES

All authors declare that there is no conflict of interest.

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.

References

- Cordell HJ (2002) Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans. *Hum Mol Genet* 11:2463–2468.
- Dayem Ullah AZ, Lemoine NR, Chelala C (2013) A practical guide for the functional annotation of genetic variations using SNPnexus. *Br Bioinform* 14:437–447. doi: 10.1093/bib/bbt004
- Dehghan A, Köttgen A, Yang Q, et al (2008) Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. *Lancet* 372:1953–1961. doi: 10.1016/S0140-6736(08)61343-4
- Dong Z, Guo S, Yang Y, et al (2015a) Association between ABCG2 Q141K polymorphism and gout risk affected by ethnicity and gender: A systematic review and meta-analysis. *Int J Rheum Dis* 18:382–391. doi: 10.1111/1756-185X.12519
- Dong Z, Li Y, Zhou J, et al (2017a) Copy number variants of ABCF1, IL17REL, and FCGR3A are associated with the risk of gout. *Protein Cell* 1–4. doi: 10.1007/s13238-017-0401-y
- Dong Z, Wang J (2015) Gout and Hyperuricemia Copy number variation and gout : the next frontier. 2:42–49. doi: 10.3966/GH1506020201
- Dong Z, Zhao D, Yang C, et al (2015b) Common variants in LRP2 and COMT genes affect the susceptibility of gout in a chinese population. *PLoS One*. doi: 10.1371/journal.pone.0131302
- Dong Z, Zhou J, Jiang S, et al (2017b) Effects of multiple genetic loci on the pathogenesis from serum urate to gout. *Sci Rep* 7:43614. doi: 10.1038/srep43614
- Guo Y, Conti D V., Wang K (2015) Enlight: Web-based integration of GWAS results with biological annotations. *Bioinformatics* 31:275–276. doi: 10.1093/bioinformatics/btu639
- Johnson AD, Handsaker RE, Pulit SL, et al (2008) SNAP: A web-based tool for identification

- and annotation of proxy SNPs using HapMap. *Bioinformatics* 24:2938–2939. doi: 10.1093/bioinformatics/btn564
- Kent WJ, Sugnet CW, Furey TS, et al (2002) The Human Genome Browser at UCSC. *Genome Res* 12:996–1006. doi: 10.1101/gr.229102
- Khanna D, Fitzgerald JD, Khanna PP, et al (2012) 2012 American college of rheumatology guidelines for management of gout. part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res* 64:1431–1446. doi: 10.1002/acr.21772
- Köttgen A, Albrecht E, Teumer A, et al (2012) Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. *Nat Genet* 45:145–154. doi: 10.1038/ng.2500
- Merriman TR (2015) An update on the genetic architecture of hyperuricemia and gout. *Arthritis Res Ther* 17:98. doi: 10.1186/s13075-015-0609-2
- Perez-Ruiz F, Dalbeth N, Bardin T (2014) A Review of Uric Acid, Crystal Deposition Disease, and Gout. *Adv. Ther.* 32:31–41.
- Phillips PC (2008) Epistasis--the essential role of gene interactions in the structure and evolution of genetic systems. *Nat Rev Genet* 9:855–67. doi: 10.1038/nrg2452
- Wallace SL, Robinson H, Masi AT, et al (1977) Preliminary criteria for the classification of the acute arthritis of primary gout. *Arthritis Rheum* 20:895–900. doi: 10.1002/art.1780200320
- Wang X, Lu M, Qian J, et al (2009) Rationales, design and recruitment of the Taizhou Longitudinal Study. *BMC Public Health* 9:223. doi: 10.1186/1471-2458-9-223
- Ward LD, Kellis M (2012) HaploReg: A resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. *Nucleic Acids*

Res. doi: 10.1093/nar/gkr917

Wei WH, Guo Y, Kindt ASD, et al (2014) Abundant local interactions in the 4p16.1 region suggest functional mechanisms underlying SLC2A9 associations with human serum uric acid. *Hum Mol Genet* 23:5061–5068. doi: 10.1093/hmg/ddu227

Woodward OM, Köttgen A, Coresh J, et al (2009) Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. *Proc Natl Acad Sci U S A* 106:10338–10342. doi: 10.1073/pnas.0901249106

Yang L, Dong Z, Zhou J, et al (2016) Common UCP2 variants contribute to serum urate concentrations and the risk of hyperuricemia. *Sci Rep* 6:27279. doi: 10.1038/srep27279

Yang Q, Köttgen A, Dehghan A, et al (2010) Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. *Circ Cardiovasc Genet* 3:523–530. doi: 10.1161/CIRCGENETICS.109.934455

Zhang Y, Liu K, Ma L, et al (2016) Associations of gout with polymorphisms in SLC2A9, WDR1, CLNK, PKD2, and ABCG2 in Chinese Han and Tibetan populations. *Int J Clin Exp Pathol* 9:7503–7517.

Zhu Y, Pandya BJ, Choi HK (2011) Prevalence of gout and hyperuricemia in the US general population: The National Health and Nutrition Examination Survey 2007-2008. *Arthritis Rheum* 63:3136–3141. doi: 10.1002/art.30520

Figure legends

Figure 1. The mRNA expression correlation between *PDK2* and *ABCG2*

Supplementary Materials

Figure S1. Chromatin state analysis of the *PKD2* and *ABCG2* gene region by Enlight

Figure S2. Chromatin state analysis of the *PKD2* and *ABCG2* gene region by UCSC genome browser

Table S1. Characteristics of participants in this study. HUA, hyperuricemia. The data are shown as the mean (SD).

Table 1. Association between serum urate and epistatic interactions of loci in *PKD2* and *ABCG2*

Chr.	SNP ₁	Pos ₁	A ₁	SNP ₂	Pos ₂	A ₂	Dist	LD (r^2)		Estimate	P_{int}	Variance explained (%)
4	rs2725215	88961571	T	rs1481012	89039082	G	77511	0.605	Male	-2.309	0.693	-
									Female	-12.817	0.236	-
									Total	-7.020	0.181	-
4	rs2725215	88961571	T	rs2231137	89061114	T	99543	0.116	Male	4.830	0.618	-
									Female	20.178	0.220	-
									Total	9.306	0.270	-
4	rs2728121	88997102	C	rs1481012	89039082	G	41980	0.370	Male	-6.051	0.379	-
									Female	-33.315	0.006	0.493
									Total	-14.487	0.018	0.099
4	rs2728121	88997102	C	rs2231137	89061114	T	64012	0.045	Male	8.980	0.017	0.144
									Female	9.250	0.171	-
									Total	9.781	0.004	0.164

Chr, chromosome of a SNP pair. SNP₁ (SNP₂), Pos₁ (Pos₂), name and position of the first (second) SNP. A₁, effect allele of SNP₁; A₂, effect allele of SNP₂. dist, distance in bp between two SNPs. LD (r^2), linkage disequilibrium between two SNPs. P_{int} , P -value of the interaction between SNP pair in serum urate was calculated by linear regression adjusted age, gender and target SNPs. Variance explained of the interaction between SNP pair in serum urate was calculated by linear regression.

Table 2. Association between SNP pairs and hyperuricemia/gout

SNP ₁	SNP ₂		<u>Hyperuricemia Vs. Control</u>			<u>Gout Vs. Hyperuricemia</u>			<u>Gout Vs. Control</u>		
			Estimate	SE	<i>P</i> _{int}	Estimate	SE	<i>P</i> _{int}	Estimate	SE	<i>P</i> _{int}
rs2728121	rs1481012	Male	-0.108	0.153	0.483	0.188	0.245	0.444	0.077	0.258	0.765
		Female	-0.648	0.272	0.017	-0.528	0.947	0.577	-0.897	0.835	0.282
		Total	-0.254	0.130	0.051	0.165	0.234	0.482	-0.004	0.239	0.987
rs2728121	rs2231137	Male	0.206	0.087	0.018	0.338	0.156	0.030	0.524	0.161	0.001
		Female	0.118	0.148	0.427	0.100	0.536	0.852	0.229	0.523	0.661
		Total	0.193	0.074	0.009	0.313	0.149	0.035	0.480	0.149	0.001

SNP₁ (SNP₂), name of the first (second) SNP. SE, standard error. *P*_{int}, *P*-value of the interaction between SNP pair in hyperuricemia and gout were calculated by logistic regression adjusted age, gender and target SNPs.

Table 3. Association between SNP pairs and serum urate in subgroups of BMI and smoking status

SNP ₁	SNP ₂		<u>Subgroup-1</u>			<u>Subgroup-2</u>			<u>Subgroup-3</u>		
			Estimate	SE	<i>P</i> _{int}	Estimate	SE	<i>P</i> _{int}	Estimate	SE	<i>P</i> _{int}
rs2728121	rs1481012	BMI	19.794	41.811	0.637	-10.483	8.306	0.207	-21.702	9.477	0.022
		Smoke	-25.467	15.210	0.095	-7.751	10.478	0.460	-9.196	8.343	0.271
rs2728121	rs2231137	BMI	24.512	22.948	0.288	11.456	4.620	0.013	9.844	4.962	0.047
		Smoke	9.972	8.385	0.235	7.106	5.223	0.174	7.592	4.608	0.100

SNP₁ (SNP₂), name of the first (second) SNP. SE, standard error. *P*_{int}, *P*-value of the interaction between SNP pair in serum urate was calculated by linear regression adjusted age, gender and target SNPs. Subgroup of BMI: 1, Underweight (BMI < 18.5); 2, Normal (18.5 ≤ BMI < 25); 3, Overweight (BMI ≥ 25). Subgroup of smoke: 1, non-smokers; 2, former smokers; 3, current smokers.

Table 4. Enhancer enrichment analysis of loci in *PKD2*

SNP sets	ID	<u>Cell type</u>	<u>All enhancers</u>				<u>Strongest enhancers</u>			
		Description	Obs	Exp	Fold	<i>P</i>	Obs	Exp	Fold	<i>P</i>
1	Huvec	umbilical vein endothelial cells	5	1.4	3.6	0.012	4	0.7	5.7	0.005
2	H1	H1 cell line	4	10.5	0.4	0.994	4	0.9	4.5	0.013
	HepG2	hepatocellular carcinoma	24	9.3	2.6	2.50E-05	24	3.1	7.8	<1.0E-06
	Huvec	umbilical vein endothelial cells	41	11.4	3.6	<1.0E-06	29	5.7	5.1	<1.0E-06
	HSMM	skeletal muscle myoblasts	30	12.9	2.3	1.80E-05	4	5.7	0.7	0.818
	NHLF	lung fibroblasts	43	11.6	3.7	<1.0E-06	15	4.4	3.4	4.20E-05
	HMEC	mammary epithelial cells	36	15	2.4	1.00E-06	10	5.7	1.7	0.065
	GM12878	B-lymphocyte, lymphoblastoid	20	11.8	1.7	0.016	13	4.3	3	4.36E-04
	NHEK	epidermal keratinocytes	30	13	2.3	2.00E-05	17	5.7	3	7.40E-05

Set one was SNPs associated with serum urate reaching genome-wide significance levels in a recent genome-wide association study. Set two was all SNPs in the gene region of *PKD2*.

